# Rebecca C Fitzgerald

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4040048/rebecca-c-fitzgerald-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

199	10,111	55	96
papers	citations	h-index	g-index
225 ext. papers	13,123 ext. citations	<b>12.1</b> avg, IF	6.18 L-index

#	Paper	IF	Citations
199	Computational pathology aids derivation of microRNA biomarker signals from Cytosponge samples <i>EBioMedicine</i> , <b>2022</b> , 76, 103814	8.8	
198	Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot <i>Lancet Oncology, The</i> , <b>2022</b> ,	21.7	1
197	Multi-omic cross-sectional cohort study of pre-malignant Barrett's esophagus reveals early structural variation and retrotransposon activity <i>Nature Communications</i> , <b>2022</b> , 13, 1407	17.4	2
196	Early detection of cancer Science, 2022, 375, eaay9040	33.3	27
195	Patient-reported experiences and views on the Cytosponge test: a mixed-methods analysis from the BEST3 trial <i>BMJ Open</i> , <b>2022</b> , 12, e054258	3	1
194	Rearrangement processes and structural variations show evidence of selection in oesophageal adenocarcinomas <i>Communications Biology</i> , <b>2022</b> , 5, 335	6.7	1
193	The future of early cancer detection <i>Nature Medicine</i> , <b>2022</b> , 28, 666-677	50.5	7
192	Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence. <i>Nature Genetics</i> , <b>2021</b> , 53, 1553-1563	36.3	12
191	Limitations of Heartburn and Other Societies' Criteria in Barrett's Screening for Detecting De Novo Esophageal Adenocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	4
190	Screening for Barrett's Oesophagus: Are We Ready for it?. <i>Current Treatment Options in Gastroenterology</i> , <b>2021</b> , 19, 1-16	2.5	0
189	Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma. <i>Nature Communications</i> , <b>2021</b> , 12, 1454	17.4	5
188	Evidence that polyploidy in esophageal adenocarcinoma originates from mitotic slippage caused by defective chromosome attachments. <i>Cell Death and Differentiation</i> , <b>2021</b> , 28, 2179-2193	12.7	3
187	Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling. <i>Annals of Oncology</i> , <b>2021</b> , 32, 522-532	10.3	18
186	Triage-driven diagnosis of Barrett's esophagus for early detection of esophageal adenocarcinoma using deep learning. <i>Nature Medicine</i> , <b>2021</b> , 27, 833-841	50.5	17
185	Chromosomal copy number heterogeneity predicts survival rates across cancers. <i>Nature Communications</i> , <b>2021</b> , 12, 3188	17.4	6
184	Economic evaluation of Cytosponge -trefoil factor 3 for Barrett esophagus: A cost-utility analysis of randomised controlled trial data. <i>EClinicalMedicine</i> , <b>2021</b> , 37, 100969	11.3	0
183	Genomic instability signals offer diagnostic possibility in early cancer detection. <i>Trends in Genetics</i> , <b>2021</b> , 37, 966-972	8.5	1

# (2020-2021)

182	Minimally invasive esophageal sponge cytology sampling is feasible in a Tanzanian community setting. <i>International Journal of Cancer</i> , <b>2021</b> , 148, 1208-1218	7.5	5
181	Single-bite versus double-bite technique for mapping biopsies during endoscopic surveillance for hereditary diffuse gastric cancer: a single-center, randomized trial. <i>Endoscopy</i> , <b>2021</b> , 53, 246-253	3.4	3
180	Hereditary Diffuse Gastric Cancer: Approaches to Screening, Surveillance, and Treatment. <i>Annual Review of Medicine</i> , <b>2021</b> , 72, 263-280	17.4	4
179	Progress in Screening for Barrett's Esophagus: Beyond Standard Upper Endoscopy. <i>Gastrointestinal Endoscopy Clinics of North America</i> , <b>2021</b> , 31, 43-58	3.3	3
178	Practical early cancer detection: distinguishing stable from unstable genomes in pre-cancerous tissues. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 683-685	8.7	1
177	Utility and Cost-Effectiveness of a Nonendoscopic Approach to Barrett's Esophagus Surveillance After Endoscopic Therapy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	1
176	Randomized Controlled Trial of the Gastrin/CCK Receptor Antagonist Netazepide in Patients with Barrett's Esophagus. <i>Cancer Prevention Research</i> , <b>2021</b> , 14, 675-682	3.2	1
175	Serial Circulating Tumor DNA Detection Using a Personalized, Tumor-Informed Assay in Esophageal Adenocarcinoma Patients Following Resection. <i>Gastroenterology</i> , <b>2021</b> , 161, 1705-1708.e2	13.3	2
174	The risk of neoplasia in patients with Barrett's esophagus indefinite for dysplasia: a multicenter cohort study. <i>Gastrointestinal Endoscopy</i> , <b>2021</b> , 94, 263-270.e2	5.2	2
173	Molecular phenotyping reveals the identity of Barrett's esophagus and its malignant transition. <i>Science</i> , <b>2021</b> , 373, 760-767	33.3	18
172	Extensive phylogenies of human development inferred from somatic mutations. <i>Nature</i> , <b>2021</b> , 597, 387	-3924	21
171	The mutational landscape of human somatic and germline cells. <i>Nature</i> , <b>2021</b> , 597, 381-386	50.4	32
170	Evolution and progression of Barrett's oesophagus to oesophageal cancer. <i>Nature Reviews Cancer</i> , <b>2021</b> , 21, 731-741	31.3	6
169	Impact of Barrett oesophagus diagnoses and endoscopies on oesophageal cancer survival in the UK: A cohort study <i>Cancer Medicine</i> , <b>2021</b> ,	4.8	2
168	Shared Genetic Etiology of Obesity-Related Traits and Barrett's Esophagus/Adenocarcinoma: Insights from Genome-Wide Association Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2020</b> , 29, 427-433	4	4
167	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. <i>Cell Reports</i> , <b>2020</b> , 31, 107550	10.6	19
166	The mutREAD method detects mutational signatures from low quantities of cancer DNA. <i>Nature Communications</i> , <b>2020</b> , 11, 3166	17.4	3
165	Aneuploidy in targeted endoscopic biopsies outperforms other tissue biomarkers in the prediction of histologic progression of Barrett's oesophagus: A multi-centre prospective cohort study. <i>EBioMedicine</i> , <b>2020</b> , 56, 102765	8.8	8

164	Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data. <i>Gastroenterology</i> , <b>2020</b> , 158, 1682-1697.e1	13.3	23
163	Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. <i>Nature Genetics</i> , <b>2020</b> , 52, 306-319	36.3	122
162	Comparison of Phenotypes and Risk Factors for Esophageal Adenocarcinoma at Present vs Prior Decades. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2710-2716.e1	6.9	4
161	Big data is crucial to the early detection of cancer. <i>Nature Medicine</i> , <b>2020</b> , 26, 19-20	50.5	9
160	Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma. <i>Nature Genetics</i> , <b>2020</b> , 52, 74-83	36.3	24
159	Role of TFF3 as an adjunct in the diagnosis of Barrett's esophagus using a minimally invasive esophageal sampling device-The Cytosponge. <i>Diagnostic Cytopathology</i> , <b>2020</b> , 48, 253-264	1.4	11
158	Development and validation of a risk prediction model to diagnose Barrett's oesophagus (MARK-BE): a case-control machine learning approach. <i>The Lancet Digital Health</i> , <b>2020</b> , 2, E37-E48	14.4	7
157	Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2701-2709.e3	6.9	8
156	Time to Challenge Current Strategies for Detection of Barrett's Esophagus and Esophageal Adenocarcinoma. <i>Digestive Diseases and Sciences</i> , <b>2020</b> , 65, 18-21	4	2
155	Use of Cytosponge as a triaging tool to upper gastrointestinal endoscopy during the COVID-19 pandemic. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 805-806	18.8	6
154	Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure. <i>Nature Genetics</i> , <b>2020</b> , 52, 1178-1188	36.3	25
153	The utility of a methylation panel in the assessment of clinical response to radiofrequency ablation for Barrett's esophagus. <i>EBioMedicine</i> , <b>2020</b> , 58, 102877	8.8	
152	Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. <i>Lancet, The</i> , <b>2020</b> , 396, 333-344	40	62
151	Hereditary diffuse gastric cancer: updated clinical practice guidelines. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, e386-e397	21.7	95
150	Endoscopic tumour morphology impacts survival in adenocarcinoma of the oesophagus. <i>European Journal of Surgical Oncology</i> , <b>2020</b> , 46, 2257-2261	3.6	
149	Genomic copy number predicts esophageal cancer years before transformation. <i>Nature Medicine</i> , <b>2020</b> , 26, 1726-1732	50.5	31
148	Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma. <i>Gastroenterology</i> , <b>2020</b> , 159, 2065-2076.e1	13.3	4
147	Machine learning to predict early recurrence after oesophageal cancer surgery. <i>British Journal of Surgery</i> , <b>2020</b> , 107, 1042-1052	5.3	14

146	Gastroesophageal reflux GWAS identifies risk loci that also associate with subsequent severe esophageal diseases. <i>Nature Communications</i> , <b>2019</b> , 10, 4219	17.4	15
145	Early detection and therapeutics. <i>Molecular Oncology</i> , <b>2019</b> , 13, 599-613	7.9	11
144	Barrett oesophagus. <i>Nature Reviews Disease Primers</i> , <b>2019</b> , 5, 35	51.1	42
143	A clinically translatable hyperspectral endoscopy (HySE) system for imaging the gastrointestinal tract. <i>Nature Communications</i> , <b>2019</b> , 10, 1902	17.4	40
142	Ingested asbestos in filtered beer, in addition to occupational exposure, as a causative factor in oesophageal adenocarcinoma. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 1099-1104	8.7	2
141	Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 3389-3401	7.5	11
140	Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. <i>Gut</i> , <b>2019</b> , 68, 1918-1927	19.2	13
139	No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2227-2235.e1	6.9	8
138	Barrett's oesophagus and oesophageal adenocarcinoma. <i>Medicine</i> , <b>2019</b> , 47, 275-285	0.6	2
137	Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining. <i>Pharmacology &amp; Therapeutics</i> , <b>2019</b> , 203, 107395	13.9	35
136	Patient-specific cancer genes contribute to recurrently perturbed pathways and establish therapeutic vulnerabilities in esophageal adenocarcinoma. <i>Nature Communications</i> , <b>2019</b> , 10, 3101	17.4	17
135	High-Fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett's Esophagus via Interleukin 8 and Alterations to the Gut Microbiome. <i>Gastroenterology</i> , <b>2019</b> , 157, 492-506.e2	13.3	58
134	The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. <i>Nature Genetics</i> , <b>2019</b> , 51, 506-516	36.3	86
133	scRNA-seq assessment of the human lung, spleen, and esophagus tissue stability after cold preservation. <i>Genome Biology</i> , <b>2019</b> , 21, 1	18.3	161
132	Feasibility of combined screening for upper gastrointestinal adenocarcinoma risk by serology and Cytosponge testing: the SUGAR study. <i>Journal of Clinical Pathology</i> , <b>2019</b> , 72, 825-829	3.9	3
131	The landscape of somatic mutation in normal colorectal epithelial cells. <i>Nature</i> , <b>2019</b> , 574, 532-537	50.4	217
130	A Deep Learning Framework for Predicting Response to Therapy in Cancer. <i>Cell Reports</i> , <b>2019</b> , 29, 336	7-3376.	e <b>4</b> 3
129	A crosssectional analysis of Facebook comments to study public perception of a new diagnostic test called the Cytosponge. <i>Ecological Management and Restoration</i> , <b>2019</b> , 32,	3	1

128	Acceptability, Accuracy, and Safety of Disposable Transnasal Capsule Endoscopy for Barrett's Esophagus Screening. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 638-646.e1	6.9	18
127	Safety and Acceptability of Esophageal Cytosponge Cell Collection Device in a Pooled Analysis of Data From Individual Patients. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 647-656.e1	6.9	38
126	A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinoma. <i>Ecological Management and Restoration</i> , <b>2019</b> , 32,	3	19
125	Conference report: improving outcomes for gastrointestinal cancer in the UK. <i>Frontline Gastroenterology</i> , <b>2018</b> , 9, 49-61	2.6	2
124	Detection of early neoplasia in Barrett's esophagus using lectin-based near-infrared imaging: an ex vivo study on human tissue. <i>Endoscopy</i> , <b>2018</b> , 50, 618-625	3.4	15
123	Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants. <i>Gastroenterology</i> , <b>2018</b> , 154, 1273-1281.e3	13.3	43
122	Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 489-498	18.8	58
121	New Screening Techniques in Barrett's Esophagus: Great Ideas or Great Practice?. <i>Gastroenterology</i> , <b>2018</b> , 154, 1594-1601	13.3	33
120	Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1598-16	06. <del>2</del> 4	14
119	Revised British Society of Gastroenterology recommendation on the diagnosis and management of Barrett's oesophagus with low-grade dysplasia. <i>Gut</i> , <b>2018</b> , 67, 392-393	19.2	59
118	Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status. <i>Gastrointestinal Endoscopy</i> , <b>2018</b> , 87, 408-418	5.2	66
117	Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics. <i>Nature Communications</i> , <b>2018</b> , 9, 2983	17.4	113
116	Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. <i>Lancet, The,</i> <b>2018</b> , 392, 400-408	40	127
115	Screening for Barrett's Esophagus: Are New High-Volume Methods Feasible?. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 2105-2114	4	4
114	Selection and Application of Tissue microRNAs for Nonendoscopic Diagnosis of Barrett's Esophagus. <i>Gastroenterology</i> , <b>2018</b> , 155, 771-783.e3	13.3	32
113	Methylation panel is a diagnostic biomarker for Barrett's oesophagus in endoscopic biopsies and non-endoscopic cytology specimens. <i>Gut</i> , <b>2018</b> , 67, 1942-1949	19.2	53
112	Endoscopic Management of Early Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus: Screening, Diagnosis, and Therapy. <i>Gastroenterology</i> , <b>2018</b> , 154, 421-436	13.3	101
111	Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts.  Gastroenterology, 2018, 155, 1720-1728.e4	13.3	46

#### (2017-2018)

110	Barrett's oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux. <i>BMC Cancer</i> , <b>2018</b> , 18, 784	4.8	29	
109	Somatic mutant clones colonize the human esophagus with age. <i>Science</i> , <b>2018</b> , 362, 911-917	33.3	465	
108	DNA Methylation Biomarkers for the Diagnosis of Barrett's Oesophagus. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 1722	0.7		
107	Organ-preserving approaches in oesophageal cancer. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 858-859	21.7	1	
106	A non-endoscopic device to sample the oesophageal microbiota: a case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 32-42	18.8	72	
105	Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 23-31	18.8	71	
104	High-risk individuals' perceptions of reproductive genetic testing for CDH1 mutations. <i>Familial Cancer</i> , <b>2017</b> , 16, 531-535	3	3	
103	Past, present and future of Barrett's oesophagus. European Journal of Surgical Oncology, 2017, 43, 114	8-3.660	11	
102	Evolutionary dynamics in pre-invasive neoplasia. <i>Current Opinion in Systems Biology</i> , <b>2017</b> , 2, 1-8	3.2	8	
101	Medicine is the ultimate personalised technology. <i>BMJ, The</i> , <b>2017</b> , 357, j1750	5.9		
100	A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy. <i>Genome Research</i> , <b>2017</b> , 27, 902-912	9.7	14	
99	International cancer seminars: a focus on esophageal squamous cell carcinoma. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2086-2093	10.3	93	
98	Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. <i>Gut</i> , <b>2017</b> , 66, 1739-1747	19.2	24	
97	Early Diagnosis of Gastroesophageal Cancers and the Cytosponge: A Work in Progress. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , <b>2017</b> , 4, 447	7.9	2	
96	Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma. <i>British Journal of Surgery</i> , <b>2017</b> , 104, 1816-	1828	55	
95	Open chromatin profiling identifies AP1 as a transcriptional regulator in oesophageal adenocarcinoma. <i>PLoS Genetics</i> , <b>2017</b> , 13, e1006879	6	28	
94	The Evolving Genomic Landscape of Barrett's Esophagus and Esophageal Adenocarcinoma. <i>Gastroenterology</i> , <b>2017</b> , 153, 657-673.e1	13.3	53	
93	Oesophageal cancer. <i>Nature Reviews Disease Primers</i> , <b>2017</b> , 3, 17048	51.1	367	

92	Accuracy and Safety of the Cytosponge for Assessing Histologic Activity in Eosinophilic Esophagitis: A Two-Center Study. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1538-1544	0.7	44
91	Alternatives to Traditional Per-Oral Endoscopy for Screening. <i>Gastrointestinal Endoscopy Clinics of North America</i> , <b>2017</b> , 27, 379-396	3.3	10
90	The Psychosocial Impact of Undergoing Prophylactic Total Gastrectomy (PTG) to Manage the Risk of Hereditary Diffuse Gastric Cancer (HDGC). <i>Journal of Genetic Counseling</i> , <b>2017</b> , 26, 752-762	2.5	21
89	Range of pathologies diagnosed using a minimally invasive capsule sponge to evaluate patients with reflux symptoms. <i>Histopathology</i> , <b>2017</b> , 70, 203-210	7.3	39
88	Application of a multi-gene next-generation sequencing panel to a non-invasive oesophageal cell-sampling device to diagnose dysplastic Barrett's oesophagus. <i>Journal of Pathology: Clinical Research</i> , <b>2017</b> , 3, 258-267	5.3	6
87	Impact of mutations in Toll-like receptor pathway genes on esophageal carcinogenesis. <i>PLoS Genetics</i> , <b>2017</b> , 13, e1006808	6	12
86	Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 1363-1373	21.7	94
85	Genetic progression of Barrett's oesophagus to oesophageal adenocarcinoma. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 403-10	8.7	36
84	Genomics of Esophageal Cancer and Biomarkers for Early Detection. <i>Advances in Experimental Medicine and Biology</i> , <b>2016</b> , 908, 237-63	3.6	6
83	Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1. <i>Scientific Reports</i> , <b>2016</b> , 6, 32417	4.9	15
82	An investigation of the factors effecting high-risk individuals' decision-making about prophylactic total gastrectomy and surveillance for hereditary diffuse gastric cancer (HDGC). <i>Familial Cancer</i> , <b>2016</b> , 15, 665-76	3	19
81	Pilot randomized crossover study comparing the efficacy of transnasal disposable endosheath with standard endoscopy to detect Barrett's esophagus. <i>Endoscopy</i> , <b>2016</b> , 48, 110-6	3.4	25
80	Whole-genome sequencing of nine esophageal adenocarcinoma cell lines. <i>F1000Research</i> , <b>2016</b> , 5, 133	63.6	12
79	Genetics and Biomarkers in Barrett Esophagus and Esophageal Adenocarcinoma <b>2016</b> , 37-60		
78	Polymorphisms in genes in the androgen pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 1146-52	7.5	10
77	The Discovery and Validation of Biomarkers for the Diagnosis of Esophageal Squamous Dysplasia and Squamous Cell Carcinoma. <i>Cancer Prevention Research</i> , <b>2016</b> , 9, 558-66	3.2	20
76	Leadership roles for women in gastroenterology: New initiatives for the new generation of gastroenterologists. <i>United European Gastroenterology Journal</i> , <b>2016</b> , 4, 815	5.3	O
75	Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. <i>Nature Genetics</i> , <b>2016</b> , 48, 1131-41	36.3	233

# (2015-2016)

74	Design and validation of a near-infrared fluorescence endoscope for detection of early esophageal malignancy. <i>Journal of Biomedical Optics</i> , <b>2016</b> , 21, 84001	3.5	17
73	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. <i>Journal of Medical Genetics</i> , <b>2015</b> , 52, 361-74	5.8	385
72	Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study. <i>PLoS Medicine</i> , <b>2015</b> , 12, e1001780	11.6	162
71	The combination of autofluorescence endoscopy and molecular biomarkers is a novel diagnostic tool for dysplasia in Barrett's oesophagus. <i>Gut</i> , <b>2015</b> , 64, 49-56	19.2	54
70	Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. <i>Nature Genetics</i> , <b>2015</b> , 47, 1038-1046	36.3	190
69	54 Evaluation of a Minimally-Invasive Cytosponge Esophageal Cell Collection System in Patients With Barrett's Esophagus. <i>Gastroenterology</i> , <b>2015</b> , 148, S-16	13.3	6
68	Screening for Barrett's Esophagus. <i>Gastroenterology</i> , <b>2015</b> , 148, 912-23	13.3	41
67	Combining simple patient-oriented tests with state-of-the-art molecular diagnostics for early diagnosis of cancer. <i>United European Gastroenterology Journal</i> , <b>2015</b> , 3, 226-9	5.3	5
66	Biomarkers in Barrett's Esophagus: Role in Diagnosis, Risk Stratification, and Prediction of Response to Therapy. <i>Gastroenterology Clinics of North America</i> , <b>2015</b> , 44, 373-90	4.4	17
65	Precision prevention of oesophageal adenocarcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2015</b> , 12, 243-8	24.2	101
64	Analysis of dysplasia in patients with Barrett's esophagus based on expression pattern of 90 genes. <i>Gastroenterology</i> , <b>2015</b> , 149, 1511-1518.e5	13.3	20
63	Autofluorescence-Directed Confocal Endomicroscopy in Combination With a Three-Biomarker Panel Can Inform Management Decisions in Barrett's Esophagus. <i>American Journal of</i> Gastroenterology, <b>2015</b> , 110, 1549-58	0.7	20
62	Mobile element insertions are frequent in oesophageal adenocarcinomas and can mislead paired-end sequencing analysis. <i>BMC Genomics</i> , <b>2015</b> , 16, 473	4.5	19
61	Accuracy, safety, and tolerability of tissue collection by Cytosponge vs endoscopy for evaluation of eosinophilic esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 77-83.e2	6.9	94
60	Biomarkers for dysplastic Barrett's: ready for prime time?. World Journal of Surgery, 2015, 39, 568-77	3.3	9
59	MiRNA-Related SNPs and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus: Post Genome-Wide Association Analysis in the BEACON Consortium. <i>PLoS ONE</i> , <b>2015</b> , 10, e0128617	3.7	21
58	Polymorphisms in Genes of Relevance for Oestrogen and Oxytocin Pathways and Risk of Barrett's Oesophagus and Oesophageal Adenocarcinoma: A Pooled Analysis from the BEACON Consortium. <i>PLoS ONE</i> , <b>2015</b> , 10, e0138738	3.7	9
57	Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett's esophagus. <i>Gastroenterology</i> , <b>2015</b> , 148, 367-78	13.3	76

56	Screening for Barrett Esophagus With a Nonendoscopic Sponge Capsule. <i>Gastroenterology and Hepatology</i> , <b>2015</b> , 11, 623-5	0.7	1
55	Body mass index, smoking, and alcohol and risks of Barrett's esophagus and esophageal adenocarcinoma: a UK prospective cohort study. <i>Digestive Diseases and Sciences</i> , <b>2014</b> , 59, 1552-9	4	34
54	British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. <i>Gut</i> , <b>2014</b> , 63, 7-42	19.2	863
53	Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. <i>Carcinogenesis</i> , <b>2014</b> , 35, 2740-7	4.6	27
52	Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. <i>Nature Genetics</i> , <b>2014</b> , 46, 837-843	36.3	240
51	Amplification of TRIM44: pairing a prognostic target with potential therapeutic strategy. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	34
50	Pilot study of cytological testing for oesophageal squamous cell dysplasia in a high-risk area in Northern Iran. <i>British Journal of Cancer</i> , <b>2014</b> , 111, 2235-41	8.7	20
49	The impact of prophylactic total gastrectomy on health-related quality of life: a prospective cohort study. <i>Annals of Surgery</i> , <b>2014</b> , 260, 87-93	7.8	29
48	Targeting care in Barrett's oesophagus. Clinical Medicine, 2014, 14 Suppl 6, s78-83	1.9	8
47	Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillance. <i>Gastrointestinal Endoscopy</i> , <b>2014</b> , 80, 78-87	5.2	63
46	Gastro-esophageal reflux disease symptoms and demographic factors as a pre-screening tool for Barrett's esophagus. <i>PLoS ONE</i> , <b>2014</b> , 9, e94163	3.7	21
45	A review of the current understanding and clinical utility of miRNAs in esophageal cancer. <i>Seminars in Cancer Biology</i> , <b>2013</b> , 23, 512-21	12.7	93
44	1004 Radiofrequency Ablation in Barrett's Esophagus With Confirmed Low-Grade Dysplasia: Interim Results of a European Multicenter Randomized Controlled Trial (SURF). <i>Gastroenterology</i> , <b>2013</b> , 144, S-187	13.3	8
43	Screening and risk stratification for Barrett's esophagus: how to limit the clinical impact of the increasing incidence of esophageal adenocarcinoma. <i>Gastroenterology Clinics of North America</i> , <b>2013</b> , 42, 155-73	4.4	12
42	Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus. <i>Gastroenterology</i> , <b>2013</b> , 144, 62-73.e6	13.3	128
41	A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. <i>Nature Genetics</i> , <b>2013</b> , 45, 1487-93	36.3	151
40	DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 878-88	12.9	61
39	Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis. <i>Journal of Pathology</i> , <b>2013</b> , 230, 118-28	9.4	30

# (2007-2013)

38	Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1576-82	2.2	60
37	Screening for oesophageal cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2012</b> , 9, 278-87	19.4	95
36	Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. <i>Nature Medicine</i> , <b>2012</b> , 18, 315-21	50.5	221
35	Identification and clinical implementation of biomarkers for Barrett's esophagus. <i>Gastroenterology</i> , <b>2012</b> , 142, 435-441.e2	13.3	42
34	Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. <i>Gastroenterology</i> , <b>2012</b> , 143, 927-35.e3	13.3	127
33	Randomized crossover study comparing efficacy of transnasal endoscopy with that of standard endoscopy to detect Barrett's esophagus. <i>Gastrointestinal Endoscopy</i> , <b>2012</b> , 75, 954-61	5.2	91
32	958 Time: A Prospective Study Combining Endoscopic Trimodal Imaging and Molecular Endpoints to Improve Risk Stratification in Barrett's Esophagus. <i>Gastroenterology</i> , <b>2012</b> , 142, S-165	13.3	6
31	Evidence for a functional role of epigenetically regulated midcluster HOXB genes in the development of Barrett esophagus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 9077-82	11.5	51
30	Developing a nonendoscopic screening test for Barrett's esophagus. <i>Biomarkers in Medicine</i> , <b>2011</b> , 5, 397-404	2.3	32
29	Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 2177-82	11.5	122
28	History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. <i>Gastroenterology</i> , <b>2010</b> , 138, 854-69	13.3	148
27	A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. <i>Gastroenterology</i> , <b>2010</b> , 139, 1995-2004.e15	13.3	116
26	Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. <i>BMJ, The</i> , <b>2010</b> , 341, c4372	5.9	232
25	Progressive silencing of p14ARF in oesophageal adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , <b>2009</b> , 13, 398-409	5.6	13
24	Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic. <i>Gut</i> , <b>2009</b> , 58, 1451-9	19.2	91
23	Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk. <i>Journal of Pathology</i> , <b>2008</b> , 216, 286-94	9.4	94
22	Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. <i>Journal of Pathology</i> , <b>2008</b> , 216, 295-306	9.4	105
21	Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms. <i>Gastroenterology</i> , <b>2007</b> , 133, 1198-209	13.3	81

20	Non-endoscopic immunocytological screening test for Barrett's oesophagus. <i>Gut</i> , <b>2007</b> , 56, 1033-4	19.2	16
19	Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 659-65	12.9	59
18	Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. <i>Gut</i> , <b>2006</b> , 55, 1810-20	19.2	103
17	Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?. <i>Gut</i> , <b>2005</b> , 54 Suppl 1, i21-6	19.2	55
16	Clinical implications of E-cadherin associated hereditary diffuse gastric cancer. <i>Gut</i> , <b>2004</b> , 53, 775-8	19.2	72
15	Review article: Barrett's oesophagus and associated adenocarcinomaa UK perspective. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 20 Suppl 8, 45-9	6.1	18
14	Surface expression of minichromosome maintenance proteins provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 2560-6	12.9	67
13	Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. <i>Gut</i> , <b>2002</b> , 50, 451-9	19.2	196
12	National clinician scientist posts. <i>BMJ, The</i> , <b>2002</b> , 325, S101	5.9	
11	Women in hospital medicine: career choices and opportunities. <i>British Journal of Hospital Medicine</i> , <b>2001</b> , 62, 778-9		1
10	Review article: Barrett's oesophagus, dysplasia and pharmacologic acid suppression. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2001</b> , 15, 269-76	6.1	44
9	Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. <i>Digestive Diseases and Sciences</i> , <b>2001</b> , 46, 1892-8	4	90
8	Altered sodium-hydrogen exchange activity is a mechanism for acid-induced hyperproliferation in Barrett's esophagus. <i>American Journal of Physiology - Renal Physiology</i> , <b>1998</b> , 275, G47-55	5.1	36
	Barrete's esophagas. American southlat of Physiology Renatt Hysiology, 1996, 213, 441 33		
7	Acid modulation of HT29 cell growth and differentiation. An in vitro model for Barrett's esophagus.  Journal of Cell Science, 1997, 110, 663-671	5.3	51
7	Acid modulation of HT29 cell growth and differentiation. An in vitro model for Barrett's esophagus.		51 9
	Acid modulation of HT29 cell growth and differentiation. An in vitro model for Barrett's esophagus. Journal of Cell Science, <b>1997</b> , 110, 663-671  Testosterone concentrations in men on chronic glucocorticosteroid therapy. Journal of the Royal		
6	Acid modulation of HT29 cell growth and differentiation. An in vitro model for Barrett's esophagus.  Journal of Cell Science, 1997, 110, 663-671  Testosterone concentrations in men on chronic glucocorticosteroid therapy. Journal of the Royal College of Physicians of London, 1997, 31, 168-70  Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model.	5·3 15.9	9 258

2 Extensive phylogenies of human development reveal variable embryonic patterns

1

The landscape of selection in 551 Esophageal Adenocarcinomas defines genomic biomarkers for the clinic

2